Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed informed consent prior to any study specific procedures~* Female or male aged ≥18 years at the time of consent~* eGFR ≥25 and ≤75 mL/min/1.73m2 (CKD-EPI Formula) at visit 1~* Evidence of increased albuminuria 3 months or more before visit 1 and UACR ≥200 and ≤5000 mg/g at visit 1~* Stable, and for the patient maximum tolerated labelled daily dose, treatment with ACE-I or ARB for at least 4 weeks before visit 1, if not medically contraindicated,~Exclusion Criteria:~* Autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or ANCA-associated vasculitis~* Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment~* History of organ transplantation~* Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor~* Type 1 diabetes mellitus~* New York Heart Association (NYHA) class IV Congestive Heart Failure at the time of enrolment~* MI, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): Patients will be randomized 1:1 to either dapagliflozin or placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching dapagliflozin.

Based on this trial design, predict the completion outcome and termination type (if applicable).